THERAMEX
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.
“Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex
“We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who could benefit from this impactful treatment. Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership. We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
www.theramex.com
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.
ELADYNOS®(abaloparatide) injection was approved by the European Medicines Agency for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
www.radiuspharm.com
FOR MEDIA AND INVESTORS ONLY
ELAD_HQ_PRESSR_009443 D.O.P 8/3/23
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran boosts DCI capabilities with dynamic AI Network Cloud solution12.5.2025 14:00:00 CEST | Press release
News summary: Hyperscalers, federal, SLED and enterprise customers need to expand AI services while managing high-performance data transport demands Adtran’s enhanced AINC-interconnect solution integrates with Dell’s AI Factory to optimize AI workloads and enable seamless scaling Solution delivers up to 50x performance acceleration, 20% GPU utilization efficiencies and 50% transport savings Adtran today announced its new AI Network Cloud (AINC)-interconnect solution, a next-generation fiber networking platform designed to support hyperscalers, federal agencies, SLED organizations and enterprises as they scale AI services. Integrating with Dell’s AI Factory, the technology dynamically adjusts optical networking capacity to meet real-time AI workloads, enabling seamless, high-speed connectivity from data center to data center and from core to edge. By supporting tokenized, sovereign AI networks and dynamic compute allocation, the solution empowers organizations to scale AI initiatives wi
HistoSonics Secures First Major Insurance Coverage for Non-Invasive Histotripsy Treatment for Liver Tumors With Blue Cross Blue Shield of Michigan12.5.2025 14:00:00 CEST | Press release
Non-Invasive Histotripsy for Liver Tumors Now Reimbursed for 4.5 Million Residents Across Michigan HistoSonics, the developer of the Edison Histotripsy System, today announced that Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network have created a new medical policy for histotripsy of the liver. The policy covers non-thermal histotripsy using the Edison® Histotripsy System for the treatment of primary and metastatic liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512714050/en/ HistoSonics Edison Histotripsy System As of February 1, 2025, histotripsy is a reimbursable procedure for the non-invasive mechanical destruction of liver tumors under CPT code 0686T, giving eligible patients in Michigan early access to this groundbreaking, non-invasive, incisionless treatment ahead of the broader policy effective date of July 1, 2025. “Liver tumors are often a leading cause of death for patients with serio
Rochon Genova: Did You Purchase Shares of Aphria Inc. (“Aphria”) After January 29, 2018 and Hold Them Until March 23, 2018 and/or December 3, 2018?12.5.2025 14:00:00 CEST | Press release
A Settlement has been reached in the global class action against Aphria and certain of its former officers and directors regarding alleged misrepresentations made in certain of Aphria’s public disclosures released between January 29, 2018 and December 3, 2018 (the “Class Action”). Aphria and the other Defendants have denied all allegations against them. The Settlement provides for the payment by the Defendants of the total amount of CAD $30,000,000 to resolve the Class Action. The Settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing by the Defendants. The Settlement has been approved by the Ontario Superior Court of Justice. The Court has appointed RicePoint Administration, Inc., d/b/a Verita Global as the Administrator of the Settlement. To be eligible for compensation, Class Members must submit a completed Claim Form to the Administrator no later than August 26, 2025. If you do not file a claim by this deadline, you will be ineligible for c
Kinaxis Supercharges BayWa r.e. Solar Trade’s Supply Chain with AI-Powered Orchestration12.5.2025 13:00:00 CEST | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, announced that BayWa r.e. Solar Trade, one of the world’s largest distributors of photovoltaic components, has implemented its AI-powered orchestration platform Maestro™ to enhance decision-making, improve resilience and scale operations. As global supply chains face increasing disruptions, BayWa r.e. Solar Trade needed a more agile, data-driven solution to maintain efficiency, meet growing demand and adapt to increasing complexities all while ensuring long-term scalability. BayWa r.e. Solar Trade was looking for a supply chain planning solution that could keep pace with its rapid expansion and growing operational complexity. Traditional Enterprise Resource Planning (ERP) systems couldn’t provide the agility required, leading to visibility gaps and slower decision-making. To scale efficiently and stay ahead of disruptions, the company turned to Maestro to accelerate planning, reduce complexity, and improve re
LTIMindtree Secures $450 Million Multi-Year Deal with Global Agribusiness Leader12.5.2025 10:30:00 CEST | Press release
LTIMindtree[NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, today announced a strategic agreement with a leader in the global agribusiness sector. This is the largest deal in the history of LTIMindtree, valued at $450 million across seven years. As a part of this deal, LTIMindtree will implement an AI-powered operating model to deliver application management, infrastructure support, and cybersecurity services. This comprehensive suite of future-ready IT services, built on platforms such as SAP S/4HANA, ServiceNow, Microsoft Azure, as well as proprietary AI frameworks, are aimed at enhancing the client’s operational efficiency, scalability, and global growth. "Securing this large deal marks a pivotal milestone as we transform to an AI-driven business model, helping our clients enhance productivity," said Venu Lambu, Chief Executive Officer (Designate) and Whole-Time Director, LTIMindtree. "We are proud to be the trusted partner for one of the world
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom